Capital Fund Management (CFM)’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-41,821
| Closed | -$10.2M | – | 691 |
|
|
2024
Q2 | $10.2M | Buy |
41,821
+11,454
| +38% | +$2.78M | 0.03% | 206 |
|
|
2024
Q1 | $4.54M | Buy |
+30,367
| New | +$4.54M | 0.01% | 337 |
|
|
2020
Q2 | – | Sell |
-8,332
| Closed | -$907K | – | 517 |
|
|
2020
Q1 | $907K | Buy |
+8,332
| New | +$907K | 0.01% | 430 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 877 |
|
|
2018
Q4 | – | Sell |
-5,127
| Closed | -$449K | – | 806 |
|
|
2018
Q3 | $449K | Buy |
+5,127
| New | +$449K | ﹤0.01% | 700 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 894 |
|
|
2018
Q1 | – | Sell |
-1,674
| Closed | -$213K | – | 845 |
|
|
2017
Q4 | $213K | Buy |
+1,674
| New | +$213K | ﹤0.01% | 808 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 786 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 764 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 834 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 864 |
|
|
2016
Q3 | – | Sell |
-49,622
| Closed | -$2.75M | – | 838 |
|
|
2016
Q2 | $2.75M | Sell |
49,622
-9,828
| -17% | -$545K | 0.03% | 352 |
|
|
2016
Q1 | $3.73M | Buy |
+59,450
| New | +$3.73M | 0.04% | 314 |
|
|
2015
Q4 | – | Sell |
-32,956
| Closed | -$2.65M | – | 741 |
|
|
2015
Q3 | $2.65M | Buy |
32,956
+22,749
| +223% | +$1.83M | 0.03% | 272 |
|
|
2015
Q2 | $1.22M | Sell |
10,207
-5,964
| -37% | -$715K | 0.02% | 357 |
|
|
2015
Q1 | $1.69M | Buy |
+16,171
| New | +$1.69M | 0.02% | 305 |
|
|
2014
Q2 | – | Sell |
-16,411
| Closed | -$1.1M | – | 739 |
|
|
2014
Q1 | $1.1M | Buy |
16,411
+1,825
| +13% | +$123K | 0.01% | 424 |
|
|
2013
Q4 | $938K | Buy |
+14,586
| New | +$938K | 0.01% | 438 |
|
|
2013
Q3 | – | Hold |
0
| – | – | – | 653 |
|